Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 7/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708189 | 0.91 | HDAC3 (0.37) | HDAC3HDAC1HDAC2NCOR2TP53 | |
| SCHEMBL7711366 | 0.91 | HDAC1 (0.37) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7704910 | 0.90 | HDAC1 (0.45) | HDAC3HDAC1HDAC2NCOR2KMT2A | |
| SCHEMBL7704965 | 0.89 | HDAC3 (0.36) | HDAC3HDAC1HDAC2NCOR2TP53 | |
| SCHEMBL7708353 | 0.89 | GRM2 (0.37) | HDAC3HDAC1HDAC2NCOR2TP53 | |
| SCHEMBL7704946 | 0.89 | ALDH1A1 (0.38) | HDAC3HDAC1HDAC2NCOR2L3MBTL1 | |
| SCHEMBL7710748 | 0.87 | CA2 (0.35) | HDAC3HDAC1HDAC2NCOR2KMT2A | |
| SCHEMBL7713435 | 0.87 | HDAC1 (0.34) | HDAC3HDAC1HDAC2NCOR2KMT2A | |
| SCHEMBL7711458 | 0.86 | HDAC3 (0.33) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL7708350 | 0.86 | NR1D1 (0.40) | HDAC3HDAC1HDAC2NCOR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |